Endocrinology, Diabetes & Metabolism Doctors in Chesapeake, VA Accepting Medicare

5 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 5

Dr. David Howell Lasseter, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 713 Volvo Pkwy Ste 101, Chesapeake, VA 23320 Phone: 757-609-3404    Fax: 757-410-7215

Dr. Ted A Tobey, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3205 Churchland Blvd, Chesapeake, VA 23321 Phone: 757-484-7822

Leroy Thomas Jackson, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3205 Churchland Blvd, Chesapeake, VA 23321 Phone: 757-484-7822    Fax: 757-484-7362

James C Larocque, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3205 Churchland Blvd, Chesapeake, VA 23321 Phone: 757-484-7822    Fax: 757-484-7362

Cesar M. Plazas-guzman, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 713 Volvo Pkwy Ste 100, Chesapeake, VA 23320 Phone: 757-609-3404    Fax: 757-410-7215

News Archive

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

Neuroscientists use novel technology-based tools to predict schizophrenia

Schizophrenia, a psychiatric disorder that affects about 1% of the population,is a leading cause of functional disability in the United States.

BioNanomatrix awarded NIH grant for nanoscale platform for single-molecule DNA mapping

BioNanomatrix, Inc. has announced receipt of a grant from the National Human Genome Research Institute of the U.S. National Institutes of Health (NIH). Under the direction of BioNanomatrix principal investigator Dr. Ming Xiao, the two-year $399,020 project will develop a nanoscale platform for single-molecule haplotyping imaging and analysis of long strands of DNA at ultra-high resolution in a massively parallel format.

Targeting ASIC-related neurotransmission may lead to new therapies for treating drug addiction

University of Iowa researchers have discovered a new form of neurotransmission that influences the long-lasting memory created by addictive drugs, like cocaine and opioids, and the subsequent craving for these drugs of abuse. Loss of this type of neurotransmission creates changes in brains cells that resemble the changes caused by drug addiction.

FDA draft guidance outlines roadmap for discussion on nanotechnology in regulated products

The U.S. Food and Drug Administration today released draft guidance to provide regulated industries with greater certainty about the use of nanotechnology, which generally involves materials made up of particles that are at least one billionth of a meter in size. The guidance outlines the agency's view on whether regulated products contain nanomaterials or involve the application of nanotechnology.

Read more Medical News

› Verified 5 days ago